Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

INTRODUCTION: For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050700/
https://www.ncbi.nlm.nih.gov/pubmed/30316010
http://dx.doi.org/10.1016/j.jtho.2018.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050700/
https://www.ncbi.nlm.nih.gov/pubmed/30316010
http://dx.doi.org/10.1016/j.jtho.2018.10.003

Ejemplares similares